Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma
about
Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylationPC4 coactivates MyoD by relieving the histone deacetylase 4-mediated inhibition of myocyte enhancer factor 2C.BRCA1 interacts with FHL2 and enhances FHL2 transactivation functionThe LIM-only protein FHL2 is a negative regulator of E4F1A family of LIM-only transcriptional coactivators: tissue-specific expression and selective activation of CREB and CREMArrest of G(1)-S progression by the p53-inducible gene PC3 is Rb dependent and relies on the inhibition of cyclin D1 transcriptionFHL2, a novel tissue-specific coactivator of the androgen receptorDRAL is a p53-responsive gene whose four and a half LIM domain protein product induces apoptosisCharacterization of two isoforms of the skeletal muscle LIM protein 1, SLIM1. Localization of SLIM1 at focal adhesions and the isoform slimmer in the nucleus of myoblasts and cytoplasm of myotubes suggests distinct roles in the cytoskeleton and in nThe LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger proteinIdentification of the LIM protein FHL2 as a coactivator of beta-cateninProline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2FHL3 is an actin-binding protein that regulates alpha-actinin-mediated actin bundling: FHL3 localizes to actin stress fibers and enhances cell spreading and stress fiber disassemblyThe LIM-only protein FHL2 interacts with beta-catenin and promotes differentiation of mouse myoblasts.Disruption of four-and-a-half LIM 2 decreases bone mineral content and bone mineral density in femur and tibia bones of female mice.TUCAN/CARDINAL and DRAL participate in a common pathway for modulation of NF-kappaB activation.Alzheimer's disease-associated presenilin 2 interacts with DRAL, an LIM-domain protein.Systematic identification of genes involved in divergent skeletal muscle growth rates of broiler and layer chickensScaffold protein FHL2 facilitates MDM2-mediated degradation of IER3 to regulate proliferation of cervical cancer cells.The T-cell oncogenic protein HOX11 activates Aldh1 expression in NIH 3T3 cells but represses its expression in mouse spleen development.Translocation of a human focal adhesion LIM-only protein, FHL2, during myofibrillogenesis and identification of LIM2 as the principal determinants of FHL2 focal adhesion localization.FHL2 expression in peritumoural fibroblasts correlates with lymphatic metastasis in sporadic but not in HNPCC-associated colon cancer.The LIM domain protein FHL2 interacts with the NR5A family of nuclear receptors and CREB to activate the inhibin-α subunit gene in ovarian granulosa cells.Expression of the transcriptional coregulator FHL2 in human breast cancer: a clinicopathologic study.Muscle giants: molecular scaffolds in sarcomerogenesis.FHL2 regulates hematopoietic stem cell functions under stress conditionsKLF8 promotes tumorigenesis, invasion and metastasis of colorectal cancer cells by transcriptional activation of FHL2.Epithelial expression of FHL2 is negatively associated with metastasis-free and overall survival in colorectal cancerThe four and a half LIM domains 2 (FHL2) regulates ovarian granulosa cell tumor progression via controlling AKT1 transcription.The FHL2 regulation in the transcriptional circuitry of human cancers.Four and a half LIM domains 2 contributes to the development of human tongue squamous cell carcinoma.FHL2 binds calcineurin and represses pathological cardiac growth.Overview of the Muscle Cytoskeleton.FHL2 (SLIM3) is not essential for cardiac development and function.FHL2 mediates tooth development and human dental pulp cell differentiation into odontoblasts, partially by interacting with Runx2.Roles of LIM proteins in cardiac hypertrophy.Interaction of TACC proteins with the FHL family: implications for ERK signaling.The four and a half LIM-domain 2 controls early cardiac cell commitment and expansion via regulating β-catenin-dependent transcription.Downregulation and antiproliferative role of FHL3 in breast cancer.FHL2 interacts with EGFR to promote glioblastoma growth.
P2860
Q24293737-4C658B1D-0B28-4183-8920-80F363FAF4DFQ24297205-C190C7E1-3C91-4117-9D7A-D90E8E947151Q24297493-BFE26D26-327F-45B7-8EA1-12FBA38A0E51Q24323174-85351FC1-263F-4D3F-AD0B-288E0172EA91Q24515126-27BD7DC5-BB6F-49BF-BAF4-836BD496F5E2Q24554293-10919210-8038-4B4B-A0E2-3652F3531628Q24601620-40A3B7A5-8545-4E0B-811C-FA584642BAD8Q24683786-BB90933E-02A2-4331-81FE-1EDFCCA2A1D8Q28144167-9A96A076-1C17-47F9-A515-44FD4F6E4A9DQ28216196-55E0900F-2C27-4983-BE47-AA93AE084B78Q28216665-15A46435-66FD-4078-833A-79F994CEFEB5Q28280935-D52013EE-129B-4BFB-A311-37E683EA8DE7Q28507893-300CA585-FB21-4BED-A1CE-D5C5AAF95DF0Q31113643-8508CA33-962E-4A50-9905-12E01F40E6D7Q33254909-F06BD33C-881B-40D8-AB6A-214965D9E446Q33292102-CE8F4CF5-0732-4373-A4EC-C17DDE78F0E7Q33292161-F0E540B0-4ECF-4C7F-8C4E-09D0D7AF6FF1Q33411086-BD23F632-E7B5-4800-99FE-5712B1AFDF92Q33586638-70DAFB21-7750-4F28-9FD4-B504325B3219Q33781653-ADEAE468-0E48-4EEF-81E9-17CF3E9086B9Q33928772-82DECF13-03BE-4244-98DC-E6D40EEDC19AQ34206722-1E74A2CE-BC96-4495-86D2-70F7B8BABB29Q34317218-312A0E27-D787-4EBA-8439-67C58995385AQ34479719-30E6671B-B2DF-4DEE-8BCB-DD85E52CD6A4Q34793699-53563EEE-853A-483F-A6C2-F489D8F740B1Q35137904-80FE1ED5-14A1-451D-9AF7-AC4C207271CCQ36413193-81A9C213-34F0-425D-B03C-296169A9F1F5Q37003274-5C4D160B-A2E5-4181-BF86-B5B7AABC059EQ37151504-3A2F1EAA-93F7-46CC-AA31-3701FDA6BD64Q38554494-D2AF089F-1B41-4147-8D37-A11043F0FAC9Q38804262-D8559C52-1588-41C7-8789-6181215CE94AQ39304395-D5A714F5-A10F-4354-BD7A-DB3C94D2F054Q39391006-0C065CF6-9D68-48AC-9DDC-AC28761C3678Q39455832-5F39F607-B226-49BB-ACF2-FF2240A57182Q40115712-F65E9F9A-324B-450C-AB86-1EA0AF2342C9Q40426734-FF0333EE-EBFF-4E4F-A6D9-62D724ED3C91Q41959511-19F9592E-C926-4DE3-9254-3E906626B63DQ42556696-317A728A-75ED-468A-A004-C03EF1F23556Q45877400-CD473724-C86A-493B-884E-237348E808E6Q47871595-87EC4BEE-4963-4239-94E3-0102E7B85296
P2860
Subtractive cloning and characterization of DRAL, a novel LIM-domain protein down-regulated in rhabdomyosarcoma
description
1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 1997
@ast
im April 1997 veröffentlichter wissenschaftlicher Artikel
@de
scientific journal article
@en
vedecký článok (publikovaný 1997/04/01)
@sk
vědecký článek publikovaný v roce 1997
@cs
wetenschappelijk artikel (gepubliceerd op 1997/04/01)
@nl
наукова стаття, опублікована у квітні 1997
@uk
научни чланак (објављен 1997/04/01)
@sr
name
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@ast
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@en
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@nl
type
label
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@ast
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@en
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@nl
prefLabel
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@ast
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@en
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@nl
P2093
P3181
P356
P1433
P1476
Subtractive cloning and charac ...... -regulated in rhabdomyosarcoma
@en
P2093
A. Remppis
B. W. Schäfer
F. A. Scholl
M. G. Mattei
P. Schwalbe
P304
P3181
P356
10.1089/DNA.1997.16.433
P577
1997-04-01T00:00:00Z